Literature DB >> 15352642

Pilot evaluation of citalopram for the relief of hot flashes.

Debra L Barton1, Charles L Loprinzi, Paul Novotny, Tait Shanafelt, Jeff Sloan, Dietlind Wahner-Roedler, Teresa A Rummans, Bradley Christensen, Shaker R Dakhill, Laura S Martin.   

Abstract

Symptoms associated with premature menopause are a significant problem for women with a history of breast cancer who cannot take hormone replacement therapy. Thus, effective nonhormonal alternatives are needed to manage hot flashes, the most prevalent symptom of menopause. Previous studies have defined that venlafaxine, an anti-depressant, is an effective treatment for such hot flashes. Based on suggestive anecdotal information, we set out to evaluate, in a pilot trial, whether the antidepressant citalopram might be a good nonhormonal treatment option to add to our armamentarium for controlling hot flashes. A prospective pilot study was developed in which patients were studied for 5 weeks, with the first week used to establish a baseline, followed by 4 weeks of treatment with citalopram. During the first week of treatment, 10 mg/day of citalopram was taken while 20 mg/day was taken during each of the following three weeks. Hot-flash diaries were completed daily, symptom diaries and quality-of-life items were completed weekly and the Profile of Mood States was completed at baseline and at week 5. Evaluable patients who completed the study had a mean hot-flash frequency reduction of 58% and a mean hot-flash score reduction of 64% from baseline to week 5. The patients finishing the study also reported decreased anger, tension and depression, as well as improved mood. This pilot trial suggests that citalopram may be an effective non-hormonal treatment for hot flashes in women who can tolerate it.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15352642

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  13 in total

1.  Validation of POMS questionnaire in postmenopausal women.

Authors:  Kathleen W Wyrwich; Holly Yu
Journal:  Qual Life Res       Date:  2011-01-29       Impact factor: 4.147

2.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

3.  Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

Authors:  Debra L Barton; Beth I LaVasseur; Jeff A Sloan; Allen N Stawis; Kathleen A Flynn; Missy Dyar; David B Johnson; Pamela J Atherton; Brent Diekmann; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

4.  Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.

Authors:  Patricia Loranca-Moreno; Juan Moises Ocampo-Godínez; Alan Rios-Espinosa; Magdalena Cruz-Luna; Carolina Garmendia-Gallardo; Merle Yasmin Hernández-Castañón; Verónica Yazmin Hernández-Hernández; Paula Mariana Sánchez-Tinoco; Alma Bajonero-Domínguez; Jael Adrián Vergara Lope-Núñez; Marco Antonio Álvarez-Pérez; José Luis González-Quiroz
Journal:  Arch Gynecol Obstet       Date:  2022-08-23       Impact factor: 2.493

5.  Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis.

Authors:  Aditya Bardia; Paul Novotny; Jeff Sloan; Deb Barton; Charles Loprinzi
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

6.  Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.

Authors:  Deirdre R Pachman; Jason M Jones; Charles L Loprinzi
Journal:  Int J Womens Health       Date:  2010-08-09

7.  Levetiracetam for the treatment of hot flashes: a phase II study.

Authors:  Susan Thompson; Aditya Bardia; Angelina Tan; Debra L Barton; Lisa Kottschade; Jeff A Sloan; Brad Christensen; DeAnne Smith; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2007-06-28       Impact factor: 3.603

Review 8.  Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Authors:  M P Goetz; A Kamal; M M Ames
Journal:  Clin Pharmacol Ther       Date:  2007-09-19       Impact factor: 6.875

Review 9.  Management of hot flashes in breast cancer survivors and men with prostate cancer.

Authors:  Vered Stearns
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

10.  Effect of escitalopram on hot flash interference: a randomized, controlled trial.

Authors:  Janet S Carpenter; Katherine A Guthrie; Joseph C Larson; Ellen W Freeman; Hadine Joffe; Susan D Reed; Kristine E Ensrud; Andrea Z LaCroix
Journal:  Fertil Steril       Date:  2012-04-03       Impact factor: 7.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.